Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC) an open-label, non-randomized, multi...

Markóczy Zsolt, Sárosi Veronika, Kudaba Iveta, Gálffy Gabriella, Turay Ülkü Yilmaz, Demirkazik Ahmet, Purkalne Gunta, Somfay Attila, Pápai-Székely Zsolt, Rásó Erzsébet, Ostoros Gyula
2018